SHAKOPEE, Minn., March 09, 2026 (GLOBE NEWSWIRE) -- Canterbury Park Holding Corporation (“Canterbury” or the “Company”) (Nasdaq: CPHC) today reported financial results for the fourth quarter and full year ended December 31, 2025. ($ in thousands, except per share data and percentages) Three Months Ended December 31, Twelve Months Ended December 31, 2025 2024 Change 2025 2024 Change Net revenues $12,446 $11,978 3.9% $59,568 $61,562 (3.2%) Net income (loss) (1) ($390) ($1,245) (68.7%) ($529) $2,113 (125.1%) Adjusted EBITDA (2) $2,288 $1,497 52.8% $9,410 $10,805 (12.9%) Basic EPS ($0.08) ($0.25) (68.0%) ($0.10) $0.42 (123.8%) Diluted EPS ($0.08) ($0.25) (68.0%) ($0.10) $0.42 (123.8%) (1) Net income and basic and diluted EPS for the twelve months ended December 31, 2024, benefited from a $1.7 million gain related to the transfer of land to a new joint venture. (2) Adjusted EBITDA, a non-GAAP measure, excludes certain items from net income, a GAAP measure. Non-GAAP financial measures are not intended to be considered in isolation from, a substitute for, or superior to GAAP results. Definitions, disclosures, and reconciliations of non-GAAP financial information are included later in the release. Adjusted EBITDA margin is Adjusted EBITDA as a percentage of net revenues. Management Commentary Randy Sampson, President and Chief Executive Officer of Canterbury Park, commented, “Fourth quarter results are consistent with historical seasonality and conclude a year of transformation and diversification. Fourth quarter revenue increased 3.9% to $12.4 million, driven largely by 5.4% growth in Casino revenue. Visitation rose in the fourth quarter, and we remain focused on increasing casino traffic through our expanded VIP programs as well as enhanced advertising and marketing initiatives. Food and Beverage revenue grew slightly in the quarter, while Pari-Mutuel revenues declined slightly because of fewer races compared to last year. Adjusted EBITDA of $2.3 million rose 53% year-ove...

Q4 net revenue of $34.1 million, representing 31% growth quarter-over-quarter FY 2025 net revenue of $106.5 million, driven by growth in MIPLYFFA® net revenue to $87.4 million 2025 EPS of $1.40 basic and $1.35 diluted Company to host conference call and webcast TODAY, March 9, 2026, at 4:30 p.m. ET BOSTON, March 09, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today reported its financial results for the fourth quarter and full year ended December 31, 2025. “MIPLYFFA is making a meaningful difference for patients with Niemann-Pick disease type C, and its strong, accelerating performance reinforces our confidence in its long-term potential,” said Neil F. McFarlane, Zevra's President and Chief Executive Officer. “We have officially relocated our global corporate headquarters to Boston, enhancing our access to a deep and highly specialized talent pool. Looking ahead, we are focused on executing against multiple near-term growth opportunities in 2026, and believe we are well-positioned to execute on our strategic priorities to create meaningful value for the rare disease community and our shareholders.” MIPLYFFA® (arimoclomol) Highlights U.S.: Received 24 MIPLYFFA prescription enrollment forms for Niemann-Pick disease type C (NPC) during Q4 2025, bringing the total to 52 in 2025 and 161 since product launch. Market access has reached 68% of covered lives, supporting broad access to MIPLYFFA. EU: A Marketing Authorisation Application for the evaluation of arimoclomol for the treatment of NPC is under review by the European Medicines Agency (EMA). Arimoclomol has been designated an Orphan Medicinal Product by the EMA. The review process is progressing as expected, and at year-end, the EMA sent their 120-day list of questions, which the Company is prepared to respond to within the regulatory 90-day clock stop period. Global Expanded ...

HOUSTON, March 09, 2026 (GLOBE NEWSWIRE) -- Amplify Energy Corp. (NYSE: AMPY) (“Amplify,” the “Company,” “us,” or “our”) announced today updates to its strategic initiatives, year-end 2025 proved reserves, operating and financial results for the fourth quarter and full-year 2025, and full-year 2026 development plans and guidance for the Company. Strategic Initiatives Update In the third quarter of 2025, Amplify communicated its strategic plan with three core tenets: (1) simplify the portfolio, (2) strengthen the balance sheet, and (3) focus resources on our assets with the highest potential upside opportunities. In 2025, the Company made significant progress on all three fronts. Key highlights include: Completed six separate transactions for total consideration of approximately $250 million (excluding certain post-closing adjustments) In the fourth quarter, Amplify closed three divestitures representing a complete exit of our interests in East Texas, Louisiana, Oklahoma, and Magnify Repaid all outstanding debt under the credit facility As of December 31, 2025, Amplify had approximately $61 million in cash and cash equivalents Continued the Beta development program and significantly reduced operating costs at Bairoil At Beta, Amplify drilled and completed four wells, that in total exceeded our pre-drill type curves At Bairoil, Amplify implemented cost saving initiatives lowering annual run-rate lease operating expenses by approximately $10 million Dan Furbee, the Company’s Chief Executive Officer stated, “We are pleased to report that our strategic plan is delivering the results we set out to achieve. Last year, we committed to simplifying our portfolio, strengthening our balance sheet, and focusing our resources on the assets that we believe have substantial long‑term value creation potential. With the successful divestiture of our East Texas and Oklahoma assets, we have executed a key milestone of that strategy. These transactions have enabled us to eliminate debt ...

It's no secret that software stocks have been sold off amid market fears of the looming threat from artificial intelligence (AI). After all, why buy multiple licenses of expensive software when AI agents can replace existing software, make it easier for companies to change software providers, and replace the work of software users? That's the logic behind the sell-off, but Nvidia's CEO Jensen Huang thinks the market is wrong. Here's why and also why PTC (PTC +0.41%) could be a great stock to buy right now. Software stock sell-off The crux of Huang's argument is that instead of AI agents replacing software tools, they will simply use them more productively. This could actually add value to some software solutions by increasing the speed and depth of the actionable insights they generate. This is no more apparent than in some industrial software stocks that act as operating systems for physical assets. One great example of this comes from PTC (NASDAQ: PTC). The company is taking advantage of the opportunity to embed AI agents into its solutions, enabling it to leverage the vast amount of digital data (originating from the physical world) generated by those solutions. PTC is embedding AI into its solutions The company's computer-aided design (CAD) and product lifecycle management (PLM) software solutions create a digital thread for a product as it's designed, manufactured, serviced, and ultimately disposed of. This creates a mass of digital data from which users can draw valuable insights to improve the whole process within a "digital loop." Consequently, PTC is embedding AI into its solutions so "AI is then applied to this contextual data and even more substantial transformations become possible for our customers," according to CEO Neil Barua on a recent earnings call. The stock has underperformed the market over the last year due to the concerns outlined earlier. Expand NASDAQ : PTC PTC Today's Change ( 0.41 %) $ 0.66 Current Price $ 163.37 Key Data Points Market Cap...

Eos Energy Enterprises (EOSE +1.06%) saw an explosive rally from 2024 to 2025, climbing 951% to a 52-week peak of $19.86 per share on Nov. 10, 2025. The stock has now fallen below $6 a share, with February alone wiping out 61.1% of its value, according to data provided by S&P Global Market Intelligence. It was a quiet month for the zinc-based battery energy storage systems (BESS) maker until Feb. 26, when it released its fourth-quarter and full-year 2025 results. Eos Energy's revenue exploded, and the company has also resolved its cash problem for now. The stock still plunged, because everything's not as rosy as it appears. Why Eos Energy stock fell despite a huge quarter Eos Energy's backlog hit $701.5 million, representing 2.8 gigawatt-hours (GWh), and Q4 revenue jumped 700% year over year to a record $58 million. The biggest driver was the completion of the company's subassembly automation at its Turtle Creek facility, allowing Eos Energy to move from manual to automated processes. By the end of 2025, Eos Energy expanded its annual production capacity to 2 GWh, a massive leap from 2024 when it was barely producing at a commercial scale. With automation online, Eos Energy's customer deliveries jumped nearly 600% in Q4, driving its revenue higher. Most importantly, management no longer doubts the company's ability to continue as a "going concern" since Eos Energy raised over $1 billion in Q4 and exited 2025 with $625 million in cash. If everything's so good, what went wrong with the stock? Expand NASDAQ : EOSE Eos Energy Enterprises Today's Change ( 1.06 %) $ 0.07 Current Price $ 6.20 Key Data Points Market Cap $2.1B Day's Range $ 5.79 - $ 6.20 52wk Range $ 3.07 - $ 19.86 Volume 906K Avg Vol 22M Gross Margin -12594.85 % Eos Energy missed its own revenue targets and reported a net loss of nearly $970 million for the full year on $114 million in revenue. Management blamed non-cash items, including fair value accounting, debt retirement charges, and stock-based compen...

Key Points Margaret Hayne sold 11,518 indirectly-held shares over two days, yielding a transaction value of ~$811,000 at an average price around $70.42 per share. The sale represented 0.0128% of shares outstanding, with all shares sold through indirect holdings and no direct holdings affected by this transaction. All shares were disposed of through indirect ownership structures attributed to family trusts and related entities detailed in the filing footnotes. Hayne retains substantial ownership — 1,176,273 direct shares and 19,638,737 indirect shares following the transaction. 10 stocks we like better than Urban Outfitters › Margaret Hayne, Co-President & Chief Creative Officer at Urban Outfitters (NASDAQ:URBN), disclosed the sale of 11,518 shares of Common Stock through indirect ownership entities on Feb. 19 and Feb. 20, 2026, with an aggregate transaction value of approximately $811,000 as reported in the SEC Form 4 filing. Transaction summary Metric Value Shares sold (indirect) 11,518 Shares traded (indirect) 11,518 Transaction value ~$811,000 Post-transaction shares (direct) 1,176,273 Post-transaction shares (indirect) 19,638,737 Post-transaction value (direct ownership) ~$80.40 million Transaction value based on SEC Form 4 weighted average purchase price ($70.42); post-transaction value based on Feb. 20, 2026 market close ($68.35). Key questions How does the transaction size compare to the median for Margaret Hayne's historical sell activity? This sale of 11,518 shares is below the historical median of 18,666 shares per sell transaction, as observed across 30 sale events since February 2023. This sale of 11,518 shares is below the historical median of 18,666 shares per sell transaction, as observed across 30 sale events since February 2023. What is the impact of this sale on Hayne's ownership capacity? The transaction reduced Hayne's aggregate direct and indirect holdings to 20,815,010 shares post-transaction, which demonstrates minimal change in overall owners...

Key facts: AMD Signs License Deal with Adeia; Launches Ryzen AI P100 Series TradingView

Key facts: Micron Technology Faces Memory Shortage; Price Targets Raised TradingView

Key Points 32,410 shares were exercised and sold for a total transaction value of ~$6.0 million on February 2, 2026. After this transaction, Tabuteau directly held 7,229 shares and indirectly held 7,344,500 shares. After recent large dispositions, this event reflects shrinking direct capacity, leaving Tabuteau with just 7,229 directly held shares versus over 7.3 million indirect shares. 10 stocks we like better than Axsome Therapeutics › Herriot Tabuteau, CEO of Axsome Therapeutics (NASDAQ:AXSM), exercised and immediately sold 32,410 common shares in an open-market transaction on February 2, 2026, as disclosed in the SEC Form 4 filing. Transaction summary Metric Value Shares sold (direct) 32,410 Transaction value $6.0 million Post-transaction shares (direct) 7,229 Post-transaction shares (indirect) 7,344,500 Post-transaction value (direct ownership) ~$1,343,726.52 Transaction value based on SEC Form 4 weighted average purchase price ($185.60); post-transaction value based on Feb. 2, 2026 market close ($185.60). Key questions How material was this sale relative to Tabuteau's direct and total ownership? This disposition reduced direct holdings by 81.76%, leaving only 7,229 shares held directly. This disposition reduced direct holdings by 81.76%, leaving only 7,229 shares held directly. What is the significance of the derivative context in this transaction? The sale was solely the result of exercising 32,410 options that were set to expire, with all shares immediately sold on the open market; no new direct or indirect share grants or purchases occurred. The sale was solely the result of exercising 32,410 options that were set to expire, with all shares immediately sold on the open market; no new direct or indirect share grants or purchases occurred. How does this event fit within Tabuteau's recent trading activity and remaining capacity? Since October 2025, Tabuteau has systematically reduced his direct stake from over 39,000 to just 7,229 shares, with the shrinking tr...

格隆汇3月10日｜美股周一收盘，道指初步收涨0.5%，标普500指数涨0.8%，纳指涨1.38%。阿斯麦(ASML.O)、AMD(AMD.O)和英特尔(INTC.O)均涨于5%一线。纳斯达克中国金龙指数收涨1.7%，哔哩哔哩(BILI.O)涨6%，理想汽车(LI.O)涨3.9%。

Design Therapeutics press release ( DSGN ): Q4 GAAP EPS of -$0.27 beats by $0.10 . Cash, cash equivalents and investment securities were $219.8 million as of December 31, 2025, which the company expects to fund its planned operations into 2029. More on Design Therapeutics Seeking Alpha’s Quant Rating on Design Therapeutics Historical earnings data for Design Therapeutics Financial information for Design Therapeutics

Oracle Corporation Class Action: Levi & Korsinsky Reminds Oracle Investors of the Pending ... bdtonline.com

BofA Maintains Buy on Amazon.com, Inc. (AMZN) Stock Insider Monkey

NVIDIA Corporation (NVDA) is Investing $2 billion in Lumentum and Coherent, Reports WSJ Insider Monkey

Lucid Group (NASDAQ:LCID) stock and Rivian Automotive (NASDAQ:RIVN) stock are jumping sharply today while Tesla (NASDAQ:TSLA) lags behind. Tesla shares are weighed down by a new federal probe into its Full Self-Driving (FSD) system and intensifying competition from Chinese electric vehicle (EV) manufacturer BYD (OTC:BYDDY). Tesla stock is down 11.23% year-to-date in 2026, while Rivian ... Lucid (LCID) and Rivian (RIVN) Stocks Jump as Oil Rises but Tesla (TSLA) Stock Lags

Lucid (LCID) and Rivian (RIVN) Stocks Jump as Oil Rises but Tesla (TSLA) Stock Lags 24/7 Wall St.

Addressing MPs, Reeves said: "I recognise that households who use heating oil face unique challenges, and so I have asked the Financial Secretary to the Treasury to lead discussions with officials and with rural and Northern Irish MPs to explore further action that we can take."

美股三大指数集体收涨 2026-03-10 04:02:25 来源： 同花顺7x24快讯 分享 文章提及标的 标准普尔500指数 -- 亚马逊 -- 苹果 -- 谷歌C -- 道琼斯工业平均指数 -- 英伟达 -- 美股三大指数集体收涨，道指（DJI）涨0.5%，纳指涨1.38%，标普500（SPX）指数涨0.83%。英伟达（NVDA）涨超2%，苹果（AAPL）涨近1%，谷歌（GOOG）涨超2%，亚马逊（AMZN）、微软（MSFT）微涨，博通（AVGO）涨超4%。

Kemi may be all in favour, but at least economic realpolitik is forcing her to take a slightly different tack There have been any number of opportunities for people to decide they wanted no part of America’s war with Iran. The first was after the US had launched its first wave of strikes. To be fair, this was the moment Keir Starmer and most of the UK reckoned enough was enough and that our involvement would be limited to defensive strikes only. You couldn’t really fault the logic. Did the UK really want to be part of a war that was illegal in most versions of international law and for which the Americans had no clear vision of how it might end? Other than Donald Trump gets bored and lets everyone else clear up his mess. Like a baby. Nor was the UK’s track record of wars in the 21st century any source of pride. Iraq, Afghanistan and Libya had all been in chaos. Iran was shaping up the same way. So Starmer decided to sit this one out. Applying the doctor’s principle of ”first, do no harm”. Continue reading...

- Tremendous activity in recent months, including receipt of Japanese marketing approval, the fifth parallel U.S. trial approval, data from pancreatic cancer trials presented at ASCO GI Symposium, and the first brain cancer treatment - - Multiple meaningful milestones targeted in the coming months, including completion of patient recruitment in the U.S. pivotal ReSTART skin cancer trial, in the U.S. pilot IMPACT pancreatic cancer trial, and in the U.S. recurrent glioblastoma multiforme feasibility trial - - $76.9 million in cash, cash equivalents & deposits provides continued balance sheet strength for clinical advancement and commercial preparation - JERUSALEM, March 09, 2026 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, reported full year 2025 financial results and provided a corporate update. "The pace of progress at Alpha Tau today is unlike anything we’ve ever seen before," said Alpha Tau Chief Executive Officer Uzi Sofer. “With a slew of meaningful announcements in the past few months, culminating most recently with our receipt of marketing approval in Japan, our first outside of Israel, and with multiple meaningful milestones targeted for the coming months, we remain laser focused on execution. Clinical trial progress remains our highest priority, with an astounding five clinical trials approved in parallel in the U.S. At the same time, we continue to build out our manufacturing capabilities in New Hampshire as well as our pre-commercial preparations, while entertaining multiple tracks of strategic dialogue with partners who show increasing excitement about the ever-expanding prospects for Alpha DaRT.” Recent Corporate Highlights: Commercial-Scale U.S. Manufacturing Milestone: In October, Alpha Tau announced the receipt of a radioactive material license for its New Hampshire manufacturing facility, its first commercial-scale facility...

葡萄牙新總統塞古羅宣誓就職，國家主席習近平致賀電，稱雙邊關係健康穩定發展。 塞古羅周一在首都里斯本到議會出席宣誓就職。葡萄牙總理蒙特內格羅、西班牙國王費利佩六世亦在場。 領導中左翼社會黨的塞古羅，指任內執政重點會是改善公共醫療體系、住房、人口老齡化等領域，並努力促進經濟增長。 國家主席習近平向他致賀電指中葡兩國建交47年來，雙邊關係始終健康穩定發展，堅持相互尊重、相互支持、運用政治智慧妥善解決澳門問題。習近平強調，高度重視中葡關係發展，願同塞古羅一同加強戰略溝通，促進高質量合作。

Oracle Corporation Class Action: Levi & Korsinsky Reminds Oracle Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 6, 2026 – ORCL marketscreener.com

塞诺龙制药公司的股价在获得美国食品药品监督管理局的有利认定后飙升了47.71%，这提升了公司前景和投资者信心。 财务概览 从财务指标的核心来看，塞诺龙制药公司是一个独特的存在。尽管最近一个季度的亏损略高于预期，但仍取得了显著进展。该公司在其癫痫和神经精神药物azetukalner的多项三期研究中成功推进，展现了其韧性。在短期财务逆境中，这一进展如同一线希望。 深入来看，塞诺龙的季度营收约为750万美元。然而，实现盈利的道路依然充满挑战，其息税前利润率为负，去年累计净亏损超过1亿美元。尽管如此，凭借近5.5亿美元的强劲现金储备，塞诺龙拥有为当前和未来计划提供资金的流动性。 从市场角度看，其市销率高达465.2倍，表明可能存在估值过高。然而，潜在投资者并未却步。其丰富的产品管线，尤其是X-TOLE2试验，为隧道尽头带来了一丝曙光，特别是对于愿意经受早期动荡以换取长期收益的利益相关者而言。 预期的市场影响 基于当前情况，塞诺龙的未来可谓雄心勃勃。Stifel和Wolfe Research的分析师都对塞诺龙的未来寄予厚望，赞扬其在癫痫疗法领域的创新投入。金融界的知名人士通过调整目标价和充满信心的认可，激发了投资者的热情，并提升了市场兴趣。 其产品线中一个全面的重磅药物开发项目标志着重大进展，这不仅可能提升公司在科学界的地位，还可能大幅增加其市值。尽管前进道路上存在明显的障碍——从临床试验的不利因素到运营亏损——但受有前景的试验结果和策略性分析师背书的鼓舞，交易员们仍对其未来前景持乐观态度。 追求突破性疗法的不懈战略动力为患者和投资者都带来了希望。所有人的目光都集中在即将发布的重要试验数据上，这些数据在生物制药领域被视为可能改变游戏规则的关键信息。 责任编辑：张俊 SF065

NEW YORK and WALTHAM, Mass., March 09, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH) (“Dianthus” or the “Company”), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases, today announced that it has commenced an underwritten public offering of $400 million of shares of its common stock or, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase shares of its common stock. In addition, Dianthus expects to grant the underwriters a 30-day option to purchase up to an additional $60 million of shares of common stock at the public offering price, less underwriting discounts and commissions. The proposed public offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering. All of the securities are being offered by Dianthus.

WARREN, N.J., March 09, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced an inducement grant for Matthew Greenhawt, MD, MBA, MSc, Chief Medical Officer of Aquestive Therapeutics (the “Company”), under the Company’s 2022 Equity Inducement Plan. The inducement grant was approved by the Company’s Compensation Committee. Under the Company’s 2022 Equity Inducement Plan, Dr. Greenhawt will receive an equity award of 75,000 Restricted Stock Units (the “Inducement RSUs”) and an equity award of 50,000 non-qualified common stock options (the “Inducement Options”), each award to be granted on March 9, 2026, which is the second full trading date following the date of the Company’s public release of annual financial results on March 5, 2026. The Inducement RSUs and the Inducement Options will vest 25% after each of the first and second anniversaries of the grant date, and 50% on the third anniversary of the grant date, subject to continued employment through the applicable grant date. The Inducement Options will have a term of ten years and an exercise price per share equal to the closing price of Aquestive’s common stock, par value $0.001 per share, on the Nasdaq Global Market on March 9, 2026, the scheduled grant date of the award. The Inducement RSUs and the Inducement Options are being granted in reliance on the employment inducement exemption provided under Nasdaq Listing Rule 5635(c)(4), and these awards were approved by the independent Compensation Committee of the Board of Directors of the Company as a material inducement for Dr. Greenhawt’s acceptance of employment with Aquestive. The Inducement RSUs and the Inducement Options were granted outside of the Company’s 2018 Equity Incentive Plan. About Aquestive Therapeutics, Inc. Aquestive is a pharmaceutical ...

Trials for DT-216P2 (RESTORE-FA) and DT-168 (FECD) Ongoing; DT-818 (DM1) Dosing in Patients Expected in the First Half of 2026 Cash and Securities of $219.8 Million as of Year-End Supports Ongoing Clinical Execution CARLSBAD, Calif., March 09, 2026 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today reported fourth quarter and full year 2025 financial results and highlighted business updates and upcoming milestones across its GeneTAC® portfolio. “The fourth quarter capped a year of strong execution and meaningful progress across our GeneTAC® portfolio,” said Pratik Shah, Ph.D., chairperson and chief executive officer of Design Therapeutics. “We enter 2026 with three clinical programs advancing toward important milestones, including the planned initiation of patient dosing in our Phase 1 trial of DT-818 in DM1 in the first half of the year and anticipated data from DT-216P2 in FA and DT-168 in FECD in the second half of 2026. Together, these anticipated milestones position us for continued execution of our strategy to build a diversified set of clinical proof-of-concept opportunities for genetic diseases with significant unmet needs.” Corporate Highlights Friedreich Ataxia (FA): Design continues to dose FA patients in its RESTORE-FA Phase 1/2 MAD trial and anticipates providing an update on the effect of DT-216P2 on endogenous frataxin levels following 12 weeks of dosing in the second half of 2026. Fuchs Endothelial Corneal Dystrophy (FECD): A Phase 2 biomarker trial of DT-168 is ongoing to evaluate safety, tolerability and corneal endothelium biomarkers in FECD patients who are scheduled for corneal transplant surgery, with data anticipated in the second half of 2026. Myotonic Dystrophy Type-1 (DM1): Design expects to begin dosing DM1 patients in its Phase 1 multiple-ascending dose (MAD) trial of DT-818, a GeneTAC ® small molecule designed to selec...

Initial MGC026 (B7-H3 ADC) Phase 1 results in mid-2026 Initial MGC028 (ADAM9 ADC) Phase 1 results in second half of 2026 Lorigerlimab Phase 2 LINNET study update in mid-2026 IND submission for MGC030, a first-in-class TOP1i-based ADC, on track for 3Q 2026 Cash, cash equivalents and marketable securities of $189.9 million as of December 31, 2025; cash runway guidance remains into late 2027 ROCKVILLE, Md., March 09, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today provided an update on its recent corporate progress, reported financial results for the year ended December 31, 2025, and highlighted anticipated data disclosure timelines for its product pipeline. “I am excited about MacroGenics' future prospects, and am inspired by the commitment of our employees over the past few quarters to sharpen our focus and advance our strategic priorities," said Eric Risser, President and CEO of MacroGenics. "Looking ahead, we anticipate several important milestones in 2026, including initial clinical data from the Phase 1 studies of MGC026 and MGC028, and from the LINNET study of lorigerlimab. Additionally, we plan to submit an IND for MGC030, a first-in-class topoisomerase I inhibitor-based ADC. Finally, with cash runway into late 2027, we believe we are well positioned to execute on our plan and drive meaningful value for our shareholders." Corporate Progress and Anticipated Milestones Innovative ADC Pipeline MacroGenics is developing potential best-in-class or first-in-class antibody-drug conjugates (ADCs) that leverage its protein engineering expertise and incorporate potent glycan-linked exatecan payloads designed to enable an expanded therapeutic window. The proprietary drug-linker platform is licensed from Synaffix B.V., a Lonza company. MacroGenics' two clinical-stage ADC programs, MGC026 and MGC028, have demonstrated acceptab...

- Transformative year for tau in AD: VY1706 clinical entry and VY7523 clinical data anticipated H2 2026 - - Validating brain-targeted capsids in humans: expect two I.V.-delivered neuro gene therapies to enter clinic H2 2026 - - Advancing Voyager NeuroShuttle™: murine study using anti-amyloid antibody supports sustained brain exposure profile - - Ended 2025 with cash position of $202 million, expected to maintain runway into 2028 - LEXINGTON, Mass., March 09, 2026 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today reported fourth quarter and full year 2025 financial and operating results. “Building on our pipeline progress in 2025, Voyager expects 2026 to be a pivotal year defined by three pillars of value creation: data on tau-targeting assets for Alzheimer’s disease, clinical entry for our novel I.V.-delivered neuro gene therapies, and advancement of our nonviral delivery platform, Voyager NeuroShuttle,” said Alfred W. Sandrock, Jr., M.D., Ph.D., Chief Executive Officer of Voyager. “With a strong cash position that is expected to provide runway into 2028, I believe Voyager is poised to execute across multiple clinical programs, further validate our platforms, and build a foundation for long-term shareholder value.” Fourth Quarter 2025 and Recent Highlights Pipeline updates: VY1706 (tau-silencing gene therapy): Voyager expects completion of a good laboratory practice (GLP) toxicology study in Q1 2026, investigational new drug (IND) application submission in Q2 2026, and first-in-human dosing in H2 2026. Following a pre-IND communication with U.S. Food and Drug Administration (FDA) in Q1 2025, Voyager completed a Type C communication with FDA in Q1 2026 and believes there to be a path to IND. VY7523 (anti-tau antibody): Multiple ascending dose (MAD) clinical trial in Alzheimer’s disease (AD) completed enrollment in Q4 2025. Tau positron emission tomography (PET)...

ST. LOUIS, March 09, 2026 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial results for the fourth quarter and full year ended December 31, 2025. “The past year saw tremendous progress with significant regulatory approvals globally, advancement of a broad pipeline of innovations, and revenue growth of over 20%. I’m proud of what our team has accomplished and excited for the year ahead,” said David Fischel, Chairman and CEO. “The highlight of the past year was achieving regulatory approvals in the United States and Europe for the GenesisX robot, MAGiC ablation catheter, and MAGiC Sweep high density mapping catheter. This core product portfolio serves as a foundation for significant commercial growth as the only robotic technology in the attractive electrophysiology market.” “The commercial contribution from these new products was modest in 2025 as we worked through challenges in ramping manufacturing of MAGiC and GenesisX. Our primary goals this year are to demonstrate the commercial success of these products, ramp manufacturing substantially, and progress a robust pipeline of additional innovations. These are being advanced in a methodical and financially prudent fashion.” Stereotaxis is focused on four key milestones this year: GenesisX Robot – Establish at least five active GenesisX programs with global Electrophysiology key opinion leaders and demonstrate the accessibility of GenesisX with rapid installations in existing labs. MAGiC & MAGiC Sweep Catheters – Ramp manufacturing of MAGiC to five hundred catheters a month by year end, transition Stereotaxis’ electrophysiology customers to MAGiC and MAGiC Sweep, and launch MAGiC with Pulsed Field Ablation in Europe. Endovascular Robotics – Demonstrate a comprehensive strategy for technological leadership in robotics across interventional cardiology and neurointerventions. Synchrony Digital Surgery S...

塔斯社援引俄罗斯总统助理Yuri Ushakov的话报道称，俄罗斯总统弗拉基米尔·普京和美国总统唐纳德·特朗普通电话，讨论了伊朗冲突相关局势以及有关乌克兰的三方谈判。 此次通话“内容十分充实，毫无疑问将对两国今后在国际政治各领域的进一步工作具有实际意义”。 责任编辑：丁文武